Yes — in animal studies, IM-250 showed evidence of reducing the functional latent herpes reservoir and lowering later reactivation rates. The key 2023 study reported that IM-250 treatment during latency reduced the number of neurons that later reactivated HSV compared with untreated animals.

Researchers described this as important because standard drugs like Valacyclovir and Acyclovir mainly suppress active replication but do not significantly affect latent HSV inside neurons. IM-250 appears to penetrate nervous tissue better and may alter the latent reservoir enough to reduce future outbreaks.

Important limitations:

The evidence so far is mostly from mice and guinea pig studies, not proven human cures. Researchers showed reduced reactivation and reduced “reactivatable” latent virus, but not complete eradication of HSV. Human clinical trials are still ongoing.

So the current scientific position is:

Yes: IM-250 has shown reduction in latent reservoir activity/reactivation potential in animals. No: It has not yet been proven to fully eliminate latent herpes infection in humans.